ScholarIQanswers from OpenAlex
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
PaperCitations, authors & open-access status
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma have?
ScholarIQcitation count
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma has 5,921 citations in the OpenAlex counts ScholarIQ stores.
When was Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma published?
ScholarIQyear
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma has 2015 year in the ScholarIQ index.
What is the open-access status of Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma?
ScholarIQoa status
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma has bronze oa status in the ScholarIQ index.
What is the DOI of Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma?
ScholarIQdoi
The DOI for Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma is on the source record.
What is the PMID of Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma?
ScholarIQpmid
The PMID for Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma is on the source record.
What is the OpenAlex record for Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma?
ScholarIQopenalex
The OpenAlex for Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma is on the source record.